Monday, November 30, 2015
Idera Pharmaceuticals, a Cambridge, Mass.-based clinical-stage biopharmaceutical company developing toll-like receptors and RNA therapeutics for patients with cancer and rare diseases, has entered into an exclusive worldwide collaboration and license agreement with GlaxoSmithKline to research, develop and commercialize selected molecules from Idera’s third-generation antisense platform for the treatment of selected targets in renal disease.
Specialist healthcare investment firm LSP, also known as Life Sciences Partners, has formed a strategic collaboration with Bristol-Myers Squibb (BMS) in which the companies will work together to identify European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
Kadmon has announced a new collaboration and license agreement with China’s Jinghua Pharmaceutical to discover, develop and commercialize Kadmon’s fully human anti-VEGFR2 and anti-PD-L1 monoclonal antibodies exclusively for Greater China. Kadmon also has licensed to Jinghua its technology and know-how to discover fully human monoclonal antibodies to develop further products for commercialization in the Chinese market.
More specialty drug innovation, greater patient access to medicines and reduced impact from patent expiries will be the primary drivers of an increase in global medicine spending of up to 30% by 2018. The increase in annual spending will spike this year when absolute growth will be about $70 billion, up from $44 billion in 2013 and $26 billion in 2012, according to new research released by the IMS Institute for Healthcare Informatics.
RenovaCare, a New York-based human organ regeneration developer, and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin, one of the world’s largest university hospitals, have partnered to validate the science behind technology for treatments of wounds, burns and other skin defects.